Individualized Diabetes Management : A Guide for Primary Care

個数:

Individualized Diabetes Management : A Guide for Primary Care

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 116 p.
  • 言語 ENG
  • 商品コード 9781498762090
  • DDC分類 616.462

Full Description

In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before.

The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE).

Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.

Contents

1. Introduction 2. Overview of type 2 diabetes, epidemiology, complications and costs 3. Challenges to glycaemic control ("Deadly Triad" of progressive disease, clinical inertia and poor adherence to management plans), how these can be overcome and how these all interlink 4. Individualised management including individualised lifestyle plans and pharmacotherapy (as emphasised in ADA/EASD Guidelines) 5. Barriers to adherence (poor tolerability- particularly weight gain and hypoglycaemia) and how modern therapies may overcome some of these problems 6. Advantages and disadvantages of new therapies - discussing each in turn, and in context of drug combinations that will be acceptable to patients and help overcome clinical inertia and poor adherence 7. Importance of multi-professional care, education, development of individualised management plans etc.

最近チェックした商品